The Latest Breaking News from Mylan

Selling cash secured puts on stocks an investor is happy to take ownership of is a great way to generate some extra income.

Income investors tend to gravitate towards covered calls, and blue-chip high yielding stocks are a great place to start.

Sen. Joe Manchin has a $9 million campaign account but could face heat for raising less than 2 percent in his home state of West Virginia.

Measles, tough weeds, and a COVID hoax.

While it's surely not worth dwelling over, it nonetheless merits note: The highest-paid CEOs and their top-level colleagues rake in more money in one year — typically way more — than most of us will see in a lifetime.

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal

Viatris Inc (NASDAQ: VTRS), previously known as Mylan, has 

Biocon Biologics Ltd has agreed to acquire Viatris Inc's (NASDAQ:VTRS) biosimilars assets for up to $3.335 billion in stock and cash. The deal value includes cash of up to $2.335 billion and Compulsorily Convertible Preference Shares in Biocon Biologics, valued at $1 billion. Viatris will also pay $50 million to Biocon Biologics to fund…

Viatris Inc's (NASDAQ: VTRS) Mylan will pull one batch of non-interchangeable Semglee, also known as insulin glargine injection.